NCT07612878 · Sanofi
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
(STRIDE)
What this study is about
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
View original scientific description
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.
Interventions
DRUG
Cohort 1: Dupilumab
medicine already approved by the FDA
OTHER
Cohort 2: usual care only
Usual care that patients receive
Primary outcome measures
Participant Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Age
Participant Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Sex
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Height in meters
Participant Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Weight in kilograms
Patients Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
BMI in kg/m\^2
Patients Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Smoking and cannabis status/type/history
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Medical History
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Baseline disease characteristics
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Emphysema status
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Disease severity
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Eosinophil value
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
COPD-relevant vaccination status
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Prior and current medications
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Previous and current comorbidities
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Reason(s) for initiation of dupilumab treatment
Patient Characteristics
Time frame: End of study (24 months after the last participant is enrolled)
Insurance Provider
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- COPD patients who are newly referred to start dupilumab treatment
- Age ≥ 40 years
- Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit
Exclusion criteria
- Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)
- Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
- Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Where
- Indianapolis, Indiana
- Durham, North Carolina
- North Richland Hills, Texas
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Aug 28, 2026 · Source of record for eligibility and locations